146 related articles for article (PubMed ID: 37069112)
21. Interplay between TERT promoter mutations and methylation culminates in chromatin accessibility and TERT expression.
Salgado C; Roelse C; Nell R; Gruis N; van Doorn R; van der Velden P
PLoS One; 2020; 15(4):e0231418. PubMed ID: 32267900
[TBL] [Abstract][Full Text] [Related]
22. Craniopharyngiomas, including Recurrent Cases, Lack TERT Promoter Hotspot Mutations.
Fujio S; Juratli TA; Takajo T; Arita K; Nagano Y; Yoshimoto K; Nayyar N; Curry WT; Martinez-Lage M; Cahill DP; Barker FG; Brastianos PK
Neurol Med Chir (Tokyo); 2021 Jun; 61(6):385-391. PubMed ID: 33967180
[TBL] [Abstract][Full Text] [Related]
23. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
Arita H; Narita Y; Fukushima S; Tateishi K; Matsushita Y; Yoshida A; Miyakita Y; Ohno M; Collins VP; Kawahara N; Shibui S; Ichimura K
Acta Neuropathol; 2013 Aug; 126(2):267-76. PubMed ID: 23764841
[TBL] [Abstract][Full Text] [Related]
24. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
[TBL] [Abstract][Full Text] [Related]
25. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
Cevik D; Yildiz G; Ozturk M
World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
[TBL] [Abstract][Full Text] [Related]
26. The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis.
Lu VM; Goyal A; Lee A; Jentoft M; Quinones-Hinojosa A; Chaichana KL
J Neurooncol; 2019 Mar; 142(1):1-10. PubMed ID: 30506498
[TBL] [Abstract][Full Text] [Related]
27.
Batista R; Lima L; Vinagre J; Pinto V; Lyra J; Máximo V; Santos L; Soares P
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023888
[TBL] [Abstract][Full Text] [Related]
28. Reactivation of telomerase in cancer.
Akincilar SC; Unal B; Tergaonkar V
Cell Mol Life Sci; 2016 Apr; 73(8):1659-70. PubMed ID: 26846696
[TBL] [Abstract][Full Text] [Related]
29. Establishment and Validation of the Detection of TERT Promoter Mutations by Human Gliomas U251 Cell Lines.
Bai H; Bai S; Li X; Zhang Y; Li Y; He F; Cheng W
Biomed Res Int; 2021; 2021():3271395. PubMed ID: 34159191
[TBL] [Abstract][Full Text] [Related]
30. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
[TBL] [Abstract][Full Text] [Related]
31.
Juratli TA; Stasik S; Zolal A; Schuster C; Richter S; Daubner D; Juratli MA; Thowe R; Hennig S; Makina M; Meinhardt M; Lautenschlaeger T; Schackert G; Krex D; Thiede C
Clin Cancer Res; 2018 Nov; 24(21):5282-5291. PubMed ID: 29941484
[No Abstract] [Full Text] [Related]
32. Understanding TERT Promoter Mutations: A Common Path to Immortality.
Bell RJ; Rube HT; Xavier-Magalhães A; Costa BM; Mancini A; Song JS; Costello JF
Mol Cancer Res; 2016 Apr; 14(4):315-23. PubMed ID: 26941407
[TBL] [Abstract][Full Text] [Related]
33. The
Hafezi F; Perez Bercoff D
Cells; 2020 Mar; 9(3):. PubMed ID: 32204305
[TBL] [Abstract][Full Text] [Related]
34. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
35. Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.
Huang HN; Chiang YC; Cheng WF; Chen CA; Lin MC; Kuo KT
Mod Pathol; 2015 Feb; 28(2):303-11. PubMed ID: 25081752
[TBL] [Abstract][Full Text] [Related]
36. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma.
Remke M; Ramaswamy V; Peacock J; Shih DJ; Koelsche C; Northcott PA; Hill N; Cavalli FM; Kool M; Wang X; Mack SC; Barszczyk M; Morrissy AS; Wu X; Agnihotri S; Luu B; Jones DT; Garzia L; Dubuc AM; Zhukova N; Vanner R; Kros JM; French PJ; Van Meir EG; Vibhakar R; Zitterbart K; Chan JA; Bognár L; Klekner A; Lach B; Jung S; Saad AG; Liau LM; Albrecht S; Zollo M; Cooper MK; Thompson RC; Delattre OO; Bourdeaut F; Doz FF; Garami M; Hauser P; Carlotti CG; Van Meter TE; Massimi L; Fults D; Pomeroy SL; Kumabe T; Ra YS; Leonard JR; Elbabaa SK; Mora J; Rubin JB; Cho YJ; McLendon RE; Bigner DD; Eberhart CG; Fouladi M; Wechsler-Reya RJ; Faria CC; Croul SE; Huang A; Bouffet E; Hawkins CE; Dirks PB; Weiss WA; Schüller U; Pollack IF; Rutkowski S; Meyronet D; Jouvet A; Fèvre-Montange M; Jabado N; Perek-Polnik M; Grajkowska WA; Kim SK; Rutka JT; Malkin D; Tabori U; Pfister SM; Korshunov A; von Deimling A; Taylor MD
Acta Neuropathol; 2013 Dec; 126(6):917-29. PubMed ID: 24174164
[TBL] [Abstract][Full Text] [Related]
37. TERT promoter mutations in primary and secondary WHO grade III meningioma.
Maier AD; Stenman A; Svahn F; Mirian C; Bartek J; Juhler M; Zedenius J; Broholm H; Mathiesen T
Brain Pathol; 2021 Jan; 31(1):61-69. PubMed ID: 32805769
[TBL] [Abstract][Full Text] [Related]
38. Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy.
Cao W; Lan J; Hu C; Kong J; Xiang L; Zhang Z; Sun Y; Zeng Z; Lei S
Aging (Albany NY); 2024 Mar; 16(6):5618-5633. PubMed ID: 38499392
[TBL] [Abstract][Full Text] [Related]
39. Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations.
Izquierdo C; Barritault M; Poncet D; Cartalat S; Joubert B; Bruna J; Jouanneau E; Guyotat J; Vasiljevic A; Fenouil T; Berthezène Y; Honnorat J; Meyronet D; Ducray F
Neurosurgery; 2019 Sep; 85(3):E448-E456. PubMed ID: 30407589
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis B Virus-Telomerase Reverse Transcriptase Promoter Integration Harnesses Host ELF4, Resulting in Telomerase Reverse Transcriptase Gene Transcription in Hepatocellular Carcinoma.
Sze KM; Ho DW; Chiu YT; Tsui YM; Chan LK; Lee JM; Chok KS; Chan AC; Tang CN; Tang VW; Lo IL; Yau DT; Cheung TT; Ng IO
Hepatology; 2021 Jan; 73(1):23-40. PubMed ID: 32170761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
